Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2012 Jul 30;11(8):1683–1692. doi: 10.1158/1535-7163.MCT-12-0006-T

Table 2.

PLK PBD In vitro binding and cellular activity for FLIP compounds (Ncap-S[pT]PNGL)

SCCP ID Abbreviation N Capping Group PLK1 PBD FP
IC50 [µM]
PLK3 PBD FP
IC50 [µM]
Apoptosis @
24hr, 30 µM
Aberrant
mitoses, @
24hr, 30 µM
5594 1G1-S[pT]PNGL graphic file with name nihms437991t1.jpg 350 ND ND ND
5598 1G2-S[pT]PNGL graphic file with name nihms437991t2.jpg 320 ND ND ND
5603 1G3-S[pT]PNGL graphic file with name nihms437991t3.jpg 250 ND ND ND
5756 2G1-S[pT]PNGL graphic file with name nihms437991t4.jpg 99 ND ND ND
5788 3G1-S[pT]PNGL graphic file with name nihms437991t5.jpg 16.5 >600 36.2% 47.9%
5827 3G2-S[pT]PNGL graphic file with name nihms437991t6.jpg 8.6 >600 55.5% 53.8%
5743 Ac-PLHS[pT]A - 2 >600 34.0% 40.3%